Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Univariate logistic regression for the predicting of a pCR irrespective of study treatment

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

  pCR Odds ratio 95% CI
  n %   
Menopausal status:     
Premenopausal 12 11.3 2.17 0.73 to 6.41
Peri-/postmenopausal 5 5.6   
Clinical tumour size:     
≤ 4 cm 12 10.5 1.81 0.61 to 5.36
> 4 cm 5 6.1   
Clinical nodal status:     
Negative 14 14.3 5.28 1.47 to 19.00
Positive 3 3.1   
Grading:     
Grade I + II 2 2.2 0.13 0.03 to 0.61
Grade III 15 14.4   
Clinical response after: 2 cycles ddAT     
cCR/cPR 12 12.6 3.07 0.95 to 9.91
cNC/cPD 4 4.5   
ER:     
0 to 9% 15 17.4 11.41 2.53 to 51.41
10 to 100% 2 1.8   
PgR:     
0 to 9% 16 13.5 11.81 1.53 to 90.97
10 to 100% 1 1.3   
Ki-67:     
0 to 15% 3 4.0 0.32 0.09 to 1.15
16 to 100% 14 11.6   
HER2:     
0 to 2+ 15 10.1 2.48 0.55 to 11.28
3+ 2 4.3   
p53:     
1 to 50% 5 5.5 0.45 0.15 to 1.33
0 + 51 to 100% 12 11.4   
bcl-2:     
0 to 1+ 16 12.9 10.52 1.36 to 81.09
2 to 3+ 1 1.4   
  1. cCR, clinical complete response; cNC, clinical no change; cPD, clinical progressive disease; cPR, clinical partial response; ER, oestrogen receptor; HER2 human epidermal growth factor receptor 2; pCR, pathological complete remission; PgR, progesterone receptor.